



VIJAYA[®]
DIAGNOSTIC
CENTRE

February 13, 2026

To
The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: VIJAYA

To
The Corporate Relations Department,
BSE Limited
BSE Scrip Code: 543350

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on Financial Results for third quarter and nine months ended December 31, 2025, which would be used in the Investors / Analysts earnings conference call scheduled to be held on **February 13, 2026, at 05:00 P.M. (IST)**.

Please take the information on record.

Thanking you,
For **Vijaya Diagnostic Centre Limited**

Hansraj Singh
Company Secretary & Compliance Officer
M. No. F11438

Encl.: As Above



**VIJAYA
DIAGNOSTIC
CENTRE** [®]



Q3 & 9M FY26 Earnings Presentation

February 13, 2026

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Vijaya Diagnostic Centre Limited (the ‘Company’)**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Note 1:

Merger (Medinova Diagnostic Services Limited, Kolkata) : Pursuant to the NCLT, Hyderabad Bench order dated 13 October 2025, Medinova Diagnostic Services Limited got merged with the Company effective 01 April 2024.

Accordingly, the financial numbers for the current period and previous period have accordingly been restated to reflect the amalgamation.



**VIJAYA
DIAGNOSTIC
CENTRE**



Q3 FY26 Performance Snapshot

Financial Performance

INR 2,052 Mn

Revenue from Operations

INR 861 Mn | 41.9%

EBITDA | EBITDA Margin %

INR 432 Mn | 21.0%

PAT | PAT Margin %

Key Metrics



1.17 Mn

Footfall

4.22 Mn

Tests



162 ⁽¹⁾

Centres



92%

B2C Revenue %



YOY Growth %

21.4%

Revenue Growth %


14.7%

Test Volume Growth %

11.8%


Footfall Growth %

Geographical Contribution



Hyderabad | RoAPT | Pune | Kolkata | Others

Wellness Share%



Wellness Share %

1. Total number of centres as at 31-Dec-25

Financial Performance

INR 5,948 Mn

Revenue from Operations

INR 2,414 Mn | 40.6%

EBITDA | EBITDA Margin %

INR 1,251 Mn | 21.0%

PAT | PAT Margin %

Key Metrics



3.47 Mn

Footfall

12.44 Mn

Tests



162 ⁽¹⁾

Centres



92%

B2C Revenue %



YOY Growth %

17.1%

Revenue Growth %


13.0%

Test Volume Growth %

10.4%


Footfall Growth %

Geographical Contribution



Hyderabad | RoAPT | Pune | Kolkata | Others

Wellness Share%



Wellness Share %

1. Total number of centres as at 31-Dec-25



Commenting on the Q3 & 9M FY26 results and future business outlook, Ms. Suprita Reddy, MD & CEO at Vijaya Diagnostic Centre Ltd. said:

“Vijaya reported a robust Q3 FY26 delivering a strong revenue growth of ~21.4%, supported by volume growth of nearly ~15%. Importantly, revenues also surpassed Q2 in absolute terms, a notable achievement considering Q3 is traditionally impacted by festive and seasonal softness.

During the quarter, we expanded our network with the successful commissioning of new hub centres in Phoolbagan & Diamond Harbour, increasing our hub footprint in West Bengal to seven. Additionally, 2 new hub centres were commissioned in our core markets of Khammam & Nandyal.


I am pleased to share that both hub centres launched in Q1 FY26 in West Bengal—Krishnanagar and Barasat—achieved break-even within just three quarters of commencing operations, well ahead of the projected timeline of one year.

We have also strengthened our leadership team with the addition of a CFO, CTO, and COO, along with key hires across our clinical and corporate functions.


Moving forward, our key areas of focus would be stabilisation of the newly launched hubs, commissioning multiple spokes across our network, continued investment in latest technology to provide better customer experience and building strong brand equities in these new geographies.”

Key Financials


Revenue from Operations (INR Mn)



EBITDA & EBITDA Margin %




PAT & PAT Margin %




Revenue Mix


Radiology vs. Pathology Breakdown %




B2C Revenue %




Wellness share %




Tests Performed (# in Mn)




Footfalls (# in Mn)




Tests / Footfalls (#)



Revenue per Test (INR)



Revenue per Footfall (INR)



Consolidated Profit & Loss Statement

(INR Mn)

Particulars	Q3 FY26	Q3 FY25	Y-o-Y	Q2 FY26	Q-o-Q	9MFY26	9MFY25	Y-o-Y	FY25	FY24	Y-o-Y
Revenue from operations	2,052.1	1,689.8	21.4%	2,015.6	1.8%	5,948.3	5,081.5	17.1%	6,813.9	5,478.1	24.4%
Cost of materials consumed	240.3	208.5	15.2%	243.2	-1.2%	697.6	626.0	11.4%	847.6	654.4	29.5%
Gross Profit	1,811.9	1,481.3	22.3%	1,772.4	2.2%	5,250.7	4,455.5	17.8%	5,966.3	4,823.7	23.7%
Gross Profit (%)	88.3%	87.7%	63 bps	87.9%	36 bps	88.3%	87.7%	59 bps	87.6%	88.1%	-49 bps
Employee benefits expense	330.4	285.5	15.7%	322.6	2.4%	969.0	837.5	15.7%	1,121.5	902.2	24.3%
Other expenses	620.9	524.4	18.4%	631.6	-1.7%	1,867.5	1,574.5	18.6%	2,112.6	1,712.5	23.4%
EBITDA	860.5	671.3	28.2%	818.3	5.2%	2,414.1	2,043.5	18.1%	2,732.2	2,209.0	23.7%
EBITDA Margin (%)	41.9%	39.7%	221 bps	40.6%	134 bps	40.6%	40.2%	37 bps	40.1%	40.3%	-23 bps
Other income	51.0	47.0	8.6%	62.5	-18.4%	184.0	127.7	44.1%	183.2	208.2	-12.0%
Depreciation and amortization expense	243.4	183.0	33.0%	222.7	9.3%	675.0	517.8	30.4%	706.0	570.0	23.9%
EBIT	668.2	535.2	24.8%	658.1	1.5%	1,923.2	1,653.5	16.3%	2,209.4	1,847.2	19.6%
Finance costs	85.9	68.2	26.0%	78.3	9.8%	239.1	195.5	22.3%	267.4	239.9	11.5%
Profit before Exceptional Items & Tax	582.2	467.0	24.7%	579.8	0.4%	1,684.1	1,457.9	15.5%	1,941.9	1,607.3	20.8%
Exceptional Items	0.0	0.0	-	0.0	-	0.0	0.0	-	10.3	20.5	-49.8%
Profit before Tax	582.2	467.0	24.7%	579.8	0.4%	1,684.1	1,457.9	15.5%	1,931.6	1,586.8	21.7%
Tax expenses	150.5	114.1	31.9%	147.0	2.4%	433.6	368.6	17.6%	493.7	390.4	26.4%
Profit before Minority Interest	431.8	353.0	22.3%	432.8	-0.2%	1,250.5	1,089.3	14.8%	1,437.9	1,196.4	20.2%
Minority Interest	0.0	0.0	-	0.0	-	0.0	0.0	-	0.0	8.1	-100.0%
Profit after Tax (PAT)	431.8	353.0	22.3%	432.8	-0.2%	1,250.5	1,089.3	14.8%	1,437.9	1,188.3	21.0%
PAT Margin (%)	21.0%	20.9%	15 bps	21.5%	-43 bps	21.0%	21.4%	-41 bps	21.1%	21.7%	-59 bps
EPS – Basic (INR)*	4.2	3.4	22.2%	4.2	-0.3%	12.2	10.6	14.7%	14.0	11.6	20.4%

*Not annualized



**VIJAYA
DIAGNOSTIC
CENTRE**



Key Developments



1 Strengthening Senior Leadership Team for the Next Leg of Growth



Chief Financial Officer (CFO)
Ankit Shah

Total Experience: 20+ years

Last Experience: Chief Financial Officer - INCOR Group (Omni Hospitals)





Chartered Accountant 

Broad areas of management includes

Finance

Budgeting

Compliance



Chief Technology Officer (CTO)
Sai Prasad

Total Experience: 20+ years

Last Experience: Director Software Engineering - UnitedHealth Group





NIT, Mysore 

Broad areas of management includes

IT - Operations

Data Security

Strategic IT initiatives



Sivaramaraju Vegesna, CFA

7 years Spent at 

➔ Rejoined the company as ➔

Chief Operating Officer (COO)

Broad areas of management includes

Operations




Sales

HR

Strategic Initiatives

2 Inaugurated a state-of-the-art Hub in Phoolbagan, West Bengal

Inaugurated State-of-the-Art Hub in Phoolbagan in the 2nd week of Dec-25 in line with our strategy of creating dense network in WB





Facility houses advanced equipment including region's 1st 3T MRI

Serves as major transit hub with densely population featuring several established private and government hospitals

3 Inaugurated a state-of-the-art Hub in Diamond Harbour, West Bengal

Inaugurated State-of-the-Art Hub in Diamond Harbour in the 2nd week of Dec-25 in line with our strategy of creating dense network in WB





5,250+ sq. ft. facility houses advanced equipment including region's 1st 3T MRI

The urban area is densely populated, featuring several prominent hospitals and excellent connectivity



4 Inaugurated a state-of-the-art Hub in Nandyal, AP

Inaugurated State-of-the-Art Hub in Nandyal in the 1st week of Oct-25 in line with our strategy of broadening presence in tier 2 / 3 geographies of our core markets




8,000 sq.f.t facility houses an automated lab & advanced equipment including region's 1st 3T MRI

Vijaya already has established footprint in Nandyal through a spoke

5 Inaugurated a state-of-the-art Hub in Khammam, Telangana

Inaugurated State-of-the-Art Hub in Khammam in the 4th week of Oct-25 in line with our strategy of broadening presence in tier 2 / 3 geographies of our core markets



10,000+ sq.ft facility houses an automated lab and advanced equipment including a 3T MRI and 160 slice cardiac CT

Marks our entry into the promising region of Khammam



**VIJAYA
DIAGNOSTIC
CENTRE**




Strategic Expansion



Inorganic Expansion Strategy

- Successfully acquired PH, Pune's largest B2C integrated diagnostic chain
- This strategic acquisition seamlessly aligns with our commitment to providing top-notch healthcare services at affordable price, reflecting our shared cultural values
- Operationalized 2 hubs in Ambegaon & Kalyani Nagar and 2 spokes under Vijaya PH Brand, following the acquisition
- Aspire to consolidate our presence gradually by building a denser network



East India Strategy

- Inaugurated 5 hubs in 9M FY26 under the Vijaya brand in West Bengal
- Employing our proven hub and spoke model, aim to replicate our success in East India by creating a dense network


Core Market Strategy

- Embracing our hub-and-spoke model, we aim to broaden our presence in concentric circles, strategically reaching Tier 1 and Tier 2 cities within AP and Telangana where our brand is highly esteemed
- Operationalized 2 hubs in Nandyal and Khammam (AP & Telangana) in October 2025

Expansion into Neighbouring State

- Inaugurated 2 hubs in HSR Layout and Yelahanka, Bengaluru in Q1 FY26
- Planning to add few more hubs in FY27

Geography	Count & Type	Tentative Timelines for Commencement
<p>Hyderabad</p>	<p>1 Spoke</p> <p>5 Spokes</p>	<p>H2 FY26</p> <p>H1 FY27</p>
<p>RoAPT</p>	<p>3 Spokes</p>	<p>H1 FY27</p>
<p>Bengaluru</p>	<p>1 Hub</p> <p>1 Spoke</p>	<p>H1 FY27</p>
<p>West Bengal</p>	<p>1 Spoke</p>	<p>H1 FY27</p>





**VIJAYA
DIAGNOSTIC
CENTRE**




Company Overview



Vijaya Diagnostic is the largest integrated B2C focused diagnostic chain in India with 162 state-of-the-art centres spread across 27 cities & towns

Evolved from a regional player to a player with presence in multiple geographies ...



... While retaining its core values of providing Quality, Reliable & Accurate Diagnostic services at Affordable prices



40+ Years of Vintage

17 labs with NABL Accreditation

Founded by Mr. Surendranath Reddy in 1981 and currently led by Ms. Suprita Reddy



27 Cities and towns across India

Largest B2C integrated Player in India



300+ Doctors

Radiologist & Pathologist network



~4.51 Mn Footfalls ⁽¹⁾


Trusted by every Age group



~16.22 Mn Tests ⁽¹⁾

Most preferred Diagnostic Centre

1. Footfall and Tests for the 12 months ended 31-Dec-25



* ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

Complete Range of Diagnostic Services under One Roof

Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience





Pathology (1) 62.9 %

Radiology (1) 37.1 %

Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets

Present in Key Geographies of AP & Telangana



69⁽¹⁾ %

Hyderabad Revenue Contribution



20⁽¹⁾ %





RoAPT Revenue Contribution

A dense network created across AP & Telangana aids in distributing patient load and offering significantly faster TAT across tests

... and Driving Geographical Diversification through Strategic Expansion




Geographical Revenue Mix





Vijaya is well-placed to attract customers in new geographies due to its integrated offering and strong emphasis on customer experience

Online Services

Enhancing Customer Experience through Seamless Online App, E-Commerce Website and Call Centre Bookings



- Access to reports online & historical medical records
- Intuitive⁽¹⁾ & user-friendly interface
- Agile customer service team
- High Brand salience
- High customer stickiness
- Organic word of mouth growth



Home Collections

Elevating Customer Experience through Home Collections




Seamless & Efficient process **Temperature Controlled Logistics** **High standards of hygiene maintained**



Pre-sealed & sterilized single-use home kit

Reaches Lab within 2 hours⁽²⁾

1. Patient can track his / her health trends over time 2. Post Collection



Advanced Software to Manage Clinical Data

Advance Laboratory Information Management System (LIMS)

Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Key Suppliers

- Long standing relationship with medical technology vendors
- At the forefront of introducing new tests by adopting the latest medical technologies
- Among the first diagnostic service provider in South India to offer PET-CT scan in 2008

Front end IT infrastructure enabling...

Standardization across our operations

Closely track key performance metrics and maintain the **Turn-Around Time (TAT)**

Reduce incidence of errors due to **Low Human Intervention**

Monitor Technical Operations

Provide **Uniform Experience** to customers from booking appointments to accessing reports online

Vijaya has been ahead of the curve in getting best-in-class & latest diagnostic equipment in India which has helped in offering high quality services



Dr. S. Surendranath Reddy
Founder & Exec. Chairman

- ✓ 40+ years of experience
- ✓ Holds Bachelor's degree in Medicine and Doctor of Medicine in Radiology



Ms. Suprita Reddy
Managing Director & Chief Executive Officer

- ✓ 22+ years of experience
- ✓ Awarded Women Leadership Award in Healthcare by ABP



Mr. Sunil Chandra Kondapally
Executive Director

- ✓ 22+ years of experience
- ✓ Holds Bachelor's degree in Electrical Engineering from Florida State University



S Geeta Reddy
Non-Executive Director

- ✓ 35+ years of experience
- ✓ BOD at Sura Agritech, Iffco Kisan, Namrata Diagnostics, etc.
- ✓ LLB from Osmania University



Dr. D Nageshwar Reddy
Non-Executive Independent Director

- ✓ Chairman of AIG ⁽¹⁾, Hyderabad
- ✓ Received Padma Shri & Padma Bhushan from Govt of India
- ✓ D.M ⁽²⁾ from PGIMER Chandigarh



Mr. Shekhar Prasad Singh
Non-Executive Independent Director

- ✓ 40+ years of experience
- ✓ Ex-Chief Secretary to Government of Telangana
- ✓ Retired IAS officer of 1983 batch



Mr. S. Murthy Chavali
Non-Executive Independent Director


- ✓ 35+ years of experience
- ✓ Ex-CEO - Aurigene Discovery Tech
- ✓ MBA from IIM, Bangalore & BTech from IIT, Madras



Dr. Manjula Anagani
Non-Executive Independent Director

- ✓ 25+ years of experience
- ✓ Clinical Director & HOD - Centre of women & childcare - Care hospitals
- ✓ Awarded Padma Shri by GOI

Shareholding Pattern as at 31st December, 2025



DIIs: Mutual Funds, AIFs and QIBs
 FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs
 Others: Retail, Bodies Corporate and others

Free Zoom Webinar | Live on YouTube | LinkedIn | Vdc Connect

Webinar on Cytogenetics in Subfertility

9th October, 2025 (Thursday) | 4:00 PM IST

Speaker
Dr. Pavani Upendram
 PhD, CGC, BGC Consultant Cytogenetics & Genetic counselor
 Vijaya Diagnostic Centre, Hyderabad

Moderator
Dr. Geeta Jahagirdar
 DCP DNB Cluster in charge
 Vijaya Diagnostic Centre, Hyderabad

Free Zoom Webinar | Live on YouTube | LinkedIn | Vdc Connect

Webinar on Diagnosis of Urinary Tract Infections

23rd October 2025 (Thursday) | 3 pm IST

Speaker
Dr. Animireddy Kishore
 MBBS, MD Microbiology
 Consultant Microbiologist, Vijaya Diagnostic Centre, Tirupati

Moderator
Dr. Vittal
 MD Microbiology
 HoD - Microbiology, Vijaya Diagnostic Centre, Himayatnagar

Free Zoom Webinar | Live on YouTube | LinkedIn | Vdc Connect

Webinar on Decoding O-RADS: A Comprehensive Approach to Adnexal Mass Characterization and Risk Stratification

7th November, 2025 (Friday) | 4:00 PM IST

Chief Guest
Dr. K. Shilpi Reddy
 Clinical Director, Head of the Department, Obstetrics and Gynaecology (OB/GYN), KIMS Cuddles, Kondapur

Speaker
Dr. K. Rohini Reddy
 M.B.B.S, MD in Radiology
 Consultant Radiologist at Vijaya Diagnostic Centre, Hyderabad

Moderator
Dr. Arun Santosh
 M.B.B.S, DNB
 Consultant Radiologist at Vijaya Diagnostic Centre, Hyderabad





**VIJAYA
DIAGNOSTIC
CENTRE**



Annexure



State-of-the-art Infrastructure (1/3)











Advanced Equipment in Place to Deliver High Quality Services (1/2)




Advanced Equipment in Place to Deliver High Quality Services (2/2)




Diagnostic Centre (Nos)



Footfalls (Mn)




Tests Performed (Mn)




Test per Footfall (Nos)


Impact of COVID-19



Revenue per Test (INR)




Revenue per Footfall (INR)




(INR Mn)


Revenue




EBIDTA




PAT



EBIDTA Margin (%)




PAT Margin (%)




Integrated business model with high B2C concentration (~93%) and a strong brand recall has resulted in Industry leading margins

Note: With effect from 01 January 2023, the Company has changed its method of depreciation on all Property, Plant and Equipment from Written Down Value ("WDV") method to Straight Line Method ("SLM"), based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets. Due to the aforesaid change, the PAT for the year Financial year ended March 31, 2023 and Financial year ended March 31, 2024 was higher by Rs 67.7 Mn and Rs 290.8 Mn respectively


Surplus Cash




CFO ⁽¹⁾ / EBIDTA (%)



RoCE Pre-Tax ⁽²⁾ (%)



RoE (%)



1. CFO = Cash flow from Operations

2. ROCE (Pre-tax): PBIT ex Other income / (Networth + Long Term Debt)

Consolidated Profit & Loss Account

(INR Mn)

Particulars	FY21	FY22	FY23	FY24	FY25
Revenue from operations	3,767	4,624	4,592	5,478	6,814
Cost of materials consumed	571	715	589	654	848
Employee benefits expense	574	707	785	902	1,122
Other expenses	962	1,165	1,398	1,712	2,113
EBITDA	1,660	2,037	1,820	2,209	2,732
EBITDA %	44.1%	44.1%	39.6%	40.3%	40.1%
Other income	118	128	142	208	183
Depreciation and amortization expense	505	527	617	570	706
EBIT	1,274	1,638	1,344	1,847	2,209
Finance costs	152	165	209	240	267
Profit before tax and exceptional items	1,121	1,474	1,135	1,607	1,942
Exceptional items	-	-	-	21	10
Profit before Tax	1,121	1,474	1,135	1,587	1,932
Tax expenses	270	367	283	390	494
Profit after Tax before Minority Interest	851	1,107	852	1,196	1,438
Minority Interest	6	10	5.8	8	-
Profit after Tax	845	1,097	846	1,188	1,438
PAT %	22.4%	23.7%	18.4%	21.7%	21.1%
EPS – Basic (INR)	8.28	10.76	8.29	11.62	13.95

(INR Mn)

Assets	Mar-21	Mar-22	Mar-23	Mar-24	Mar-25
NON-CURRENT ASSETS	3,022	4,436	5,777	7,714	9,664
Property, plant and equipment	1,358	1,966	2,940	3,785	4,469
Capital work-in-progress	82	341	271	83	703
Goodwill	53	53	53	1,192	1,192
Other intangible assets	6	14	22	207	219
Right of use asset	1,260	1,672	2,223	2,235	2,768
Intangible assets under development	12	1	6	5	0
Financial assets					
- Investments	0	0	0	0	0
- Other financial assets	122	75	90	113	165
Deferred tax assets	61	89	83	29	0
Income tax assets	6	2	2	2	12
Other assets	61	223	85	62	136
CURRENT ASSETS	2,388	2,698	2,757	2,113	3,072
Inventories	26	43	20	52	49
Financial assets					
- Investments	276	542	1,390	1,091	1,846
- Trade receivables	64	98	95	162	148
- Cash and cash equivalents	67	110	242	222	128
- Bank balances other than Cash and cash equivalents	1,876	1,813	922	508	361
- Loans	0	0	0	0	0
- Other financial assets	52	51	36	31	478
Other current assets	27	41	51	46	62
TOTAL ASSETS	5,409	7,135	8,534	9,828	12,736

Equity & Liabilities	Mar-21	Mar-22	Mar-23	Mar-24	Mar-25
EQUITY	3,592	4,695	5,466	6,599	7,991
Equity share capital	45	102	102	102	102
Instruments entirely equity in nature	-	-	-	-	-
Other equity	3,547	4,593	5,364	6,497	7,889
Non-Controlling Interest					
NON-CURRENT LIABILITIES	1,377	1,778	2,406	2,500	3,119
Financial liabilities					
- Borrowings	33	0	0	0	0
- Lease liabilities	1,265	1,703	2,330	2,391	2,964
- Other financial liabilities	2	0	0	0	0
Provisions	77	74	71	106	99
Other liabilities	1	1	5	3	3
Deferred tax liabilities	-	-	-	-	53
CURRENT LIABILITIES	440	661	662	729	1,626
Financial liabilities					
- Borrowings	12	6	0	0	0
- Lease liabilities	101	126	145	201	232
- Trade payables	222	216	277	329	330
- Other financial liabilities	61	248	140	114	925
Income tax liabilities	16	9	24	12	35
Provisions	7	21	40	32	60
Other current liabilities	20	35	36	40	44
TOTAL EQUITY AND LIABILITIES	5,409	7,135	8,534	9,828	12,736

Consolidated Cash Flow Statement

(INR Mn)

Particulars	Mar-21	Mar-22	Mar-23	Mar-24	Mar-25
Cash Flow from Operating Activities					
Profit before Tax	1,121	1,474	1,135	1,587	1,932
Adjustment for Non-Operating Items	534	572	683	599	786
Operating Profit before Working Capital Changes	1,655	2,046	1,818	2,186	2,720
Changes in Working Capital	-46	-67	90	-14	-74
Cash Generated from Operations	1,609	1,979	1,908	2,172	2,644
Less: Direct Taxes paid	-312	-399	-262	-339	-399
Net Cash from Operating Activities	1,297	1,580	1,646	1,833	2,245
Purchase and construction of property, plant and building (net)	-312	-1,223	-1,248	-880	-955
Acquisition of subsidiary	-	-	-	-1,475	-
Investments (net)	-1,033	-127	734	530	-893
Others	47	120	887	401	29
Cash Flow from Investing Activities	-1,298	-1,231	-1,096	-1,423	-1,819
Cash Flow from Financing Activities	-488	-306	-419	-445	-520
Net increase/ (decrease) in Cash & Cash equivalent	-489	44	131	-36	-94
Cash & Cash Equivalents at the beginning of the period	556	67	110	258	222
Cash & Cash equivalents at the end of the period	67	110	242	222	128

Surplus Cash

Particulars	Mar-21	Mar-22	Mar-23	Mar-24	Mar-25
Investments*	335	542	1,390	1,092	1,846
Cash and cash equivalents	67	110	242	222	128
Bank balances other than Cash and cash equivalents**	1,876	1,813	922	537	843
Less: Deferred Capital Creditors					750
Total	2,277	2,465	2,554	1,851	2,067

*Current investments + investments with maturity more than 12 months (part of other non-current financial assets)

** Includes all the fixed deposits



**VIJAYA
DIAGNOSTIC
CENTRE**

Thank You

For further information please contact:

Mr. Dhiren Gala
AGM - Strategy & Investor Relations
+91 90598 93206

dhiren.g@vijayadiagnostic.in
ir@vijayadiagnostic.in

www.vijayadiagnostic.com



Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.